Survodutide, a dual glucagon and GLP-1 receptor activator, improves insulin function and sensitivity in people with type 2 diabetes or overweight

Survodutide was associated with significant improvements in beta-cell function and insulin sensitivity in participants with type 2 diabetes.

• In trial 1404-0002, survodutide led to rapid increases in beta-cell function (HOMA-β) and decreases in insulin resistance (HOMA-IR) compared to placebo.
• Participants receiving survodutide experienced significant reductions in glucagon levels and fasting plasma glucose (FPG).
• In trial 1404-0036, survodutide did not significantly change beta-cell function due to the participants being normoglycaemic, but it still reduced insulin resistance and fasting insulin levels.
• Both trials showed that the changes in fasting insulin and insulin resistance were largely independent of bodyweight changes.
• The durability of improvements in beta-cell function after stopping treatment is currently unknown.

Simplified